ArticleAlzheimer's & dementia (New York, N. Y.)2022

Effect of masupirdine (SUVN-502) on cognition in patients with moderate Alzheimer's disease: A randomized, double-blind, phase 2, proof-of-concept study.

Ramakrishna Nirogi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.